

## Summary of Material Modifications

The Public Health Emergency, which imposed group health plan mandates for coverage of COVID-19 testing and COVID-19 preventive services (such as vaccines) is scheduled to end on May 11, 2023.

Upon the termination of the Public Health Emergency, HPi will amend your group health plan accordingly for COVID-19 related benefits as follows:

- Cost sharing (e.g. deductibles, copayments or coinsurance) and prior authorization or other medical management requirements will reapply for COVID-19 testing and diagnosis. This includes in- and out-of-network telehealth visits, office visits, ER visits and urgent care visits related to determining the need for a test or the actual test, and any related medical services during that time;
- Cost sharing will reapply for any other inpatient or outpatient COVID-19 treatment services the Plan Sponsor may have waived during the COVID-19 pandemic;
- Cost sharing will reapply for coverage of FDA approved at-home over-the-counter COVID-19 tests; and
- Cost sharing will reapply for out-of-network coverage of COVID-19 preventive care and/or vaccinations.

*NOTE: Cost sharing will continue to be waived for in-network coverage of COVID-19 preventive care and/or vaccinations as in accordance with the ACA as preventive care.*

Under your Rx benefit through OptumRx effective May 12<sup>th</sup> COVID-19 coverage will be the below:

- **COVID-19 vaccine coverage will continue**
  - Coverage of Advisory Committee of Immunization Practices (ACIP) recommended and Centers for Disease Control and Prevention (CDC) adopted COVID-19 vaccine and booster serum and administration will continue when in network, and in accordance with applicable state law.
    - Claims will process through the standard pharmacy network, and pharmacists will continue to administer vaccines at retail pharmacies.
  - In accordance with the Affordable Care Act (ACA) Preventive Drug List, COVID-19 and other standard vaccines will continue to be available for members at \$0 cost-share.
- **Optum Rx COVID-19 antiviral coverage will continue**
  - Coverage of FDA approved or authorized COVID-19 treatments, including Paxlovid and molnupiravir (Lagevrio), will continue in accordance with your plans' standard benefits and applicable state law after May 11, 2023.
    - Claims will process through your plans' standard pharmacy network.
- **Optum Rx COVID-19 test kit coverage to end May 11, 2023**
  - Coverage of COVID-19 test kits at \$0 member cost-share will end for plans using our Optum Rx standard formularies after May 11, 2023.

*As a reminder, COVID-19 vaccines and antivirals that are not yet approved by the U.S. Food and Drug Administration (FDA) will be placed on Tier 3 for standard Optum Rx formularies. When these vaccines and antivirals receive FDA approval, tiering will be reevaluated and applicable changes will be made through the standard review process.*